Intellia Therapeutics, Inc. (21)

Browse by Contract Category

Contracts

Underwriting Agreement, dated as of November 30, 2022, by and between the Company and Goldman Sachs & Co. LLC (Filed With SEC on December 1, 2022)
Amended and Restated Corporate Bonus Plan (Filed With SEC on August 4, 2022)
Consent to Assignments, Licensing and Common Ownership and Invention Management Agreement dated December 15, 2016 by and between the Registrant, CRISPR Therapeutics AG, The... (Filed With SEC on February 24, 2022)
Amendment #3 to License and Collaborative Research Agreement, dated as of June 14, 2021, by and between Novartis and Intellia (Filed With SEC on June 17, 2021)
Second Amendment to Lease, dated as of March 12, 2020, by and between the Company and MIT 130 Brookline Leasehold LLC (Filed With SEC on May 7, 2020)
Description of Certain Registrants Securities (Filed With SEC on February 27, 2020)
Retirement Policy for Equity Awards (Filed With SEC on August 4, 2022)
Underwriting Agreement, dated as of June 29, 2021, by and among the Company and Goldman Sachs & Co LLC, Jefferies LLC, SVB Leerink LLC, and Barclays Capital Inc., as... (Filed With SEC on July 2, 2021)
Fourth Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on May 6, 2021)
License and Collaborative Research Agreement dated as of December 18, 2014 by and between Registrant and Novartis Institutes for BioMedical Research, Inc (Filed With SEC on May 6, 2021)
License Agreement dated as of July 16, 2014 by and between Registrant (as successor in interest of Intellia Therapeutics, LLC) and Caribou Biosciences, Inc (Filed With SEC on May 6, 2021)
Third Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on February 26, 2021)
Underwriting Agreement, dated as of December 1, 2020, by and among the Company and Goldman Sachs & Co LLC, Jefferies LLC, and SVB Leerink LLC, as representatives of the several... (Filed With SEC on December 2, 2020)
Corporate Bonus Plan, effective April 3, 2020 (Filed With SEC on August 6, 2020)
Underwriting Agreement, dated as of June 2, 2020, by and among the Company and Goldman Sachs & Co. LLC, Jefferies LLC, and SVB Leerink LLC, as representatives of the several... (Filed With SEC on June 3, 2020)
Stock Purchase Agreement, dated May 30, 2020, by and between Intellia Therapeutics, Inc. and Regeneron Pharmaceuticals, Inc (Filed With SEC on June 1, 2020)
Amendment No. 1, dated May 30, 2020, to the License and Collaboration Agreement, dated April 11, 2016, by and between Intellia Therapeutics, Inc. and Regeneron Pharmaceuticals, Inc (Filed With SEC on June 1, 2020)
Lease, dated as of March 12, 2020, by and between the Company and 281-295 Albany Street Leasehold LLC (Filed With SEC on May 7, 2020)
Second Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on February 27, 2020)
First Amendment to Lease, dated as of April 5, 2019, by and between the Company and MIT 130 Brookline Leasehold LLC (Filed With SEC on May 2, 2019)
Agreement and Amendment to License and Collaborative Research Agreement, dated as of December 3, 2018, by and between Novartis and the Company (Filed With SEC on February 27, 2019)